Angina

Clinical Trial Finder

Many patients with angina are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Mi-RNAs and Specificity of Hs-TnT in Symptomatic ED Patients

Conditions:   Coronary Artery Disease;   Myocardial Infarction
Intervention:  
Sponsors:   University Hospital Heidelberg;   German Heart Research Foundation
Not yet recruiting - verified April 2014

Copeptin Testing During Pre-hospital Care in the Treatment of Chest Pain Suggestive of Acute Coronary Syndrome

Condition:   Chest Pain
Interventions:   Biological: Blood work in the ambulance;   Biological: Blood work upon arrival in the emergency room;   Biological: Blood work at 3 hours post-arrival in the emergency room
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified April 2014

Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes

Condition:   Acute Coronary Syndromes
Intervention:   Other: blood sample
Sponsor:   Assistance Publique Hopitaux De Marseille
Not yet recruiting - verified April 2014

Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Intervention:  
Sponsors:   British Cardiac Research Trust;   Royal Free Hospital NHS Foundation Trust;   North West London Hospitals NHS Trust;   Barnet and Chase Farm Hospitals NHS Trust;   Diabetes and Obesity Research Network;   Lund University;   Health Diagnostic Laboratory, Inc.
Recruiting - verified April 2014

DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

Condition:   Coronary Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Placebo
Sponsors:   University of Edinburgh;   AstraZeneca
Not yet recruiting - verified April 2014

Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography

Condition:   Contrast Induced Nephropathy
Intervention:   Drug: Atorvastatin
Sponsor:   Isfahan University of Medical Sciences
Recruiting - verified April 2014

Antiplatelet Therapy Following Stent Implantation

Conditions:   Acute Myocardial Infarction;   Coronary Syndrome;   Angina, Unstable
Intervention:  
Sponsor:   Elpen Pharmaceutical Co. Inc.
Recruiting - verified January 2014

BIOFLOW III Satellite-ELADIS

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   C.E.M. Biotronik, S.A.
Recruiting - verified February 2014

Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: Metoprolol;   Drug: Diltiazem
Sponsor:   CAMC Health System
Recruiting - verified April 2014

EYESHOT (EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian Coronary Care Units)

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsors:   Heart Care Foundation;   Centro Servizi ANMCO S.r.l.;   AstraZeneca
Completed - verified March 2014

Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes

Condition:   Acute Kidney Injury
Intervention:  
Sponsor:   Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2014

The Evaluation Of PF-04950615 (RN316) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: PF-04950615;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

The Evaluation Of PF-04950615 (RN316), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: PF-04950615;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

HsTnT in Stable Coronary Artery Disease

Condition:   Coronary Artery Disease
Intervention:   Other: Progress of CHD
Sponsors:   University Hospital Heidelberg;   AstraZeneca
Active, not recruiting - verified April 2014

In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program

Condition:   Ischemic Heart Disease
Intervention:  
Sponsor:   Piedmont Healthcare
Recruiting - verified April 2014

BIOFLOW III Asia Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Diabetes Mellitus Type 1 or 2
Intervention:  
Sponsor:   BIOTRONIK Asia Pacific Pte Ltd
Recruiting - verified February 2014

CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

BIOFLOW-III Israel Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Diabetes Mellitus Type 1 or 2
Intervention:  
Sponsor:   BIOTRONIK Israel
Recruiting - verified July 2013

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified April 2014

BIOFLOW-III Canada Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik Canada Inc
Not yet recruiting - verified June 2013

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified April 2014

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Device: Evolocumab (AMG 145);   Device: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Recruiting - verified April 2014

Tailored Antiplatelet Therapy Following PCI

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome;   Stenosis
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor;   Genetic: Retrospective Genotype testing;   Genetic: Prospective Genotype testing
Sponsors:   Mayo Clinic;   Applied Health Research Centre (AHRC), Toronto, Canada
Recruiting - verified April 2014

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

BIOFLOW-III Austria Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik Vertriebs-GmbH
Recruiting - verified April 2013

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2014

Invasive vs Conservative Strategies in Non-ST-elevation Acute Coronary Syndrome and Comorbidities

Condition:   Acute Coronary Syndrome
Intervention:   Procedure: Coronary angiogram
Sponsors:   University of Valencia;   Instituto de Salud Carlos III
Active, not recruiting - verified April 2014

Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy

Condition:   Coronary Heart Disease (CHD)
Interventions:   Other: Treatment of CHD risk factors;   Drug: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.;   Drug: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.;   Procedure: PCA;   Procedure: CABG;   Device: Cardiospec;   Drug: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril
Sponsor:   City Hospital No 40, Saint Petersburg, Russia
Withdrawn - verified April 2014

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified April 2014

ProspEctive First Evaluation in Chest Pain Trial

Conditions:   Chest Pain;   Shortness of Breath;   Suspected Acute Coronary Syndrome
Interventions:   Procedure: Coronary CT Angiography;   Procedure: Stress Test
Sponsor:   St. Luke's-Roosevelt Hospital Center
Recruiting - verified May 2012

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition:   Smoking Cessation
Interventions:   Drug: placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
Sponsor:   Pfizer
Recruiting - verified April 2014

Clearance Of Mucus In Stents

Conditions:   Lung Neoplasms;   Respiratory Failure;   Pneumonia;   Acute Coronary Syndromes;   Unstable Angina;   Myocardial Infarction;   Cardiac Arrhythmia;   Thromboembolic Disease
Interventions:   Other: Normal Saline;   Other: Sodium Bicarbonate
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified April 2014

A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition:   Cardiovascular Disease, Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra/Actemra];   Drug: etanercept
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified April 2014

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781);   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781);   Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781)
Sponsor:   Bayer
Recruiting - verified April 2014

Collaborative Cardiac Care Project

Conditions:   Myocardial Ischemia;   Angina Pectoris;   Coronary Disease
Interventions:   Procedure: Collaborative care model;   Procedure: Group interventions;   Procedure: Facilitated consultation
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Get CardioSmart

You're Invited